DE602005026811D1 - Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns - Google Patents

Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns

Info

Publication number
DE602005026811D1
DE602005026811D1 DE602005026811T DE602005026811T DE602005026811D1 DE 602005026811 D1 DE602005026811 D1 DE 602005026811D1 DE 602005026811 T DE602005026811 T DE 602005026811T DE 602005026811 T DE602005026811 T DE 602005026811T DE 602005026811 D1 DE602005026811 D1 DE 602005026811D1
Authority
DE
Germany
Prior art keywords
foxm1b
tumor cell
sirna molecules
sirns
foxm1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005026811T
Other languages
English (en)
Inventor
Robert Costa
I-Ching Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois
Original Assignee
University of Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois filed Critical University of Illinois
Publication of DE602005026811D1 publication Critical patent/DE602005026811D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602005026811T 2004-06-22 2005-01-06 Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns Active DE602005026811D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58214104P 2004-06-22 2004-06-22
PCT/US2005/000276 WO2006009575A1 (en) 2004-06-22 2005-01-06 METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA

Publications (1)

Publication Number Publication Date
DE602005026811D1 true DE602005026811D1 (de) 2011-04-21

Family

ID=34960668

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005026811T Active DE602005026811D1 (de) 2004-06-22 2005-01-06 Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns

Country Status (6)

Country Link
US (1) US20100098663A2 (de)
EP (2) EP1758999B1 (de)
JP (1) JP4852539B2 (de)
AT (1) ATE501252T1 (de)
DE (1) DE602005026811D1 (de)
WO (1) WO2006009575A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635673B2 (en) 2003-03-25 2009-12-22 The Board Of Trustees Of The University Of Illinois Methods of inhibiting tumor cell proliferation
US8029980B2 (en) 2006-09-29 2011-10-04 The Board Of Trustees Of The University Of Illinois Identification and use of agents that modulate oncogenic transcription agent activity
JP6238319B2 (ja) * 2013-03-27 2017-11-29 国立大学法人 長崎大学 創傷または線維症の治療剤
MX2016001963A (es) 2013-08-19 2016-05-26 Hoffmann La Roche Metodo de seleccion.
JP6884102B2 (ja) * 2015-02-09 2021-06-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための化合物
EP3053577A1 (de) 2015-02-09 2016-08-10 F. Hoffmann-La Roche AG Verbindungen zur Krebsbehandlung
WO2024106737A1 (ko) * 2022-11-16 2024-05-23 한양대학교 에리카산학협력단 Foxm1 돌연변이체 또는 foxm1 shrna를 포함하는 암 치료용 약학 조성물

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (de) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmazeutische Zusammensetzung mit Gehalt an Urokinase
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
CA1310924C (en) 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5089475A (en) * 1989-02-07 1992-02-18 Brigham And Women's Hospital Treatment of ventilator dependency with growth hormone
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5672510A (en) 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
JPH08500481A (ja) 1992-05-11 1996-01-23 リボザイム・ファーマシューティカルズ・インコーポレーテッド ウイルスの複製を阻害するための方法および薬剤
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5902880A (en) 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
WO1996018736A2 (en) 1994-12-13 1996-06-20 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
EP0832269A1 (de) 1995-06-07 1998-04-01 Baylor College Of Medicine Nukleinsäure transporter zur abgabe von nukleinsäure in zellen
US5723313A (en) * 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle
US6407062B1 (en) * 1995-09-27 2002-06-18 St. Jude Children's Research Hospital ARF-P19, a novel regulator of the mammalian cell cycle
US5679559A (en) 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
CA2301166A1 (en) 1997-07-24 1999-02-04 Yuan-Peng Zhang Liposomal compositions for the delivery of nucleic acid catalysts
AR013269A1 (es) 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
AU1922999A (en) 1997-12-16 1999-07-05 Baylor College Of Medicine Needle-free injection of formulated nucleic acid molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6613750B2 (en) * 1998-03-19 2003-09-02 Albert Einstein College Of Medicine Of Yeshiva University Method of inhibiting cell proliferation using an anti-oncogene protein
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
EP1147204A1 (de) 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Zusammensetzung und verfahren zur in vivo und in vitro abschwächung der genexpression mittels dobbelsträngigem rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
MXPA01009073A (es) 1999-03-10 2002-05-06 Phogen Ltd Suministro de acidos nucleicos y proteinas a las celulas.
EP1235842A4 (de) 1999-10-15 2003-04-23 Univ Massachusetts Gene des rns-interferenzweges als hilfsmittel der gezielten gentischen interferenz
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
GB9930519D0 (en) * 1999-12-24 2000-02-16 Phogen Limited Uses of transport proteins
US20020156023A1 (en) * 2000-12-06 2002-10-24 Tularik Inc. Lometrexol combination therapy
US20040023390A1 (en) * 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
WO2004018676A2 (en) * 2002-08-21 2004-03-04 The University Of British Columbia Rnai probes targeting cancer-related proteins
US20040109844A1 (en) * 2002-08-28 2004-06-10 The Board Of Trustees Of The University Of Illinois Methods of treating age-related defects and diseases
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US7635673B2 (en) * 2003-03-25 2009-12-22 The Board Of Trustees Of The University Of Illinois Methods of inhibiting tumor cell proliferation
US7625716B2 (en) * 2003-11-26 2009-12-01 Vanderbilt University Methods for assessing p19-Arf interactions in cMyc
JP5782185B2 (ja) 2012-06-01 2015-09-24 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9507178B1 (en) 2013-08-29 2016-11-29 Charles Wesley Blackledge Electromagnetic waveguide assembly
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
US20100098663A2 (en) 2010-04-22
EP1758999A1 (de) 2007-03-07
EP2298896A1 (de) 2011-03-23
WO2006009575A1 (en) 2006-01-26
JP4852539B2 (ja) 2012-01-11
US20090075376A1 (en) 2009-03-19
EP1758999B1 (de) 2011-03-09
JP2008503234A (ja) 2008-02-07
ATE501252T1 (de) 2011-03-15

Similar Documents

Publication Publication Date Title
ATE477337T1 (de) Zusammensetzungen und verfahren zur sirna-hemmung von icam-1
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
DE602005026811D1 (de) Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
IL190796A (en) Composition containing nucleic acid encoded by anti-osteoclastogenic protein
DE602005027700D1 (de) Verfahren zur nukleinsäureimmobilisierung
ATE397676T1 (de) Identifikation und verwendung von mirnas zur differenzierung myelogener leukämiezellen
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
UA95244C2 (ru) Соединения и способ модулирования активности киназ, и показания для их применения
DE602005018981D1 (de) Verfahren zur Herstellung von L-Cystein, und L-Cystein-produzierender Mikroorganismus
DK2019692T3 (da) Forbindelser og fremgangsmåder til modulation af ekspression af gccr
MX2007002382A (es) Producci??n de anticuerpos anti-amiloides beta.
ATE533502T1 (de) Verfahren zur modulation der il-23-aktivität; relevante reagenzien
DE602005023877D1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
MY148468A (en) Compounds and methods for kinase modulation, and indications therefor
ATE517896T1 (de) P38-kinase-inhibitoren
DE602005021684D1 (de) Verfahren zur herstellung von pimecrolimus
DE602005020643D1 (de) Verfahren zur aktivierung von nkt-zellen
ATE406351T1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
DE602006016735D1 (de) Verfahren zur proliferation von stammzellen
EP2184609A3 (de) Zusammensetzungen und Verfahren zur Behandlung von Lungenkrebs
DE602005018081D1 (de) Stabiler kreatinin-biosensor mit drei enzymen
EA200701707A1 (ru) Пиразолопиримидины
BRPI0600777A (pt) método e sistema para a criação, armazenamento, gerenciamento e consumo de dados especìficos de cultura
ATE454458T1 (de) Pflanzen mit verbesserten wachstumseigenschaften und verfahren zu deren herstellung
EA200800011A1 (ru) Тиенопиримидиновые и тиенопиридиновые модуляторы киназы